The application of theranostics in different stages of prostate cancer
Details
Publication Year 2021-09,Volume 17,Issue #27,Page 3637-3644
Journal Title
Future Oncology
Publication Type
Review
Abstract
Despite the remarkable achievements in treating metastatic prostate cancer over the last two decades, castrate-resistant status is still considered the lethal stage of the disease. Theranostics combines a targeting compound (ligand) with a therapeutic radioisotope (radioactive particle) injected into the blood to target the cancer cells. The most studied radioligand is (177)Lu-PSMA-617, which targets PSMA, a protein found in prostate cancer cells. This new approach has shown promising results in treating metastatic castration-resistant prostate cancer. Currently, many trials are using PSMA-targeting radioligands in combination with conventional therapies in advanced prostate cancer or even in the earlier stages of the disease. Other preclinical trials are exploring the possibility of using newer ligands or radioisotopes to treat prostate cancer to increase the specificity and efficacy of this treatment.
Keywords
Clinical Trials as Topic; Humans; Lutetium/therapeutic use; Male; Neoplasm Staging; *Precision Medicine/trends; Prostate-Specific Antigen/therapeutic use; Prostatic Neoplasms/pathology/*radiotherapy; Radiopharmaceuticals/therapeutic use; Radiotherapy/methods; 177Lu-PSMA-617; LuPSMA; Psma; targeted radionuclide therapy; theranostics in prostate cancer
Department(s)
Cancer Imaging; Surgical Oncology
PubMed ID
34227404
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-05-23 04:02:50
Last Modified: 2025-05-23 04:04:10

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙